Online inquiry

IVTScrip™ mRNA-Anti-C5, h5G1.1HuG2/G4(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) (CAT#: GTTS-WQ8097MR)

This product GTTS-WQ8097MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets C5 gene. The antibody can be applied in Dermatomyositis, Nephritis, Atypical hemolytic uremic syndrome (aHUS) research.

Specifications
Product type	mRNA
Modified bases	5-Methyl-CTP
5' Cap	Cap 0
Species	Humanized
RefSeq	NM_001317163.2
Applications	Gene therapy research
Format	Powder
Quantity	100 µg
Purification	oligo-dT affinity purification

Target Gene
Gene ID	727
UniProt ID	P01031

Download
Download resources about mRNA therapeutics development to boost your research.

CUSTOMER REVIEWS and Q&As
There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-C5, h5G1.1HuG2/G4(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ8097MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT	Product Name	Product Type	CDs
GTTS-WQ5921MR	IVTScrip™ mRNA-Anti-CD274, CK-301(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))	mRNA	CK-301
GTTS-WQ6765MR	IVTScrip™ mRNA-Anti-TACSTD2, DS-1062(Cap 1, Pseudo-UTP, 30 nt-poly(A))	mRNA	DS-1062
GTTS-WQ11138MR	IVTScrip™ mRNA-Anti-IFNA1, MDX-1103(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A))	mRNA	MDX-1103
GTTS-WQ8694MR	IVTScrip™ mRNA-Anti-F3, HuMax-TF(Cap 1, Pseudo-UTP, 120 nt-poly(A))	mRNA	HuMax-TF
GTTS-WQ11656MR	IVTScrip™ mRNA-Anti-HA, MHAA4549A(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))	mRNA	MHAA4549A
GTTS-WQ5675MR	IVTScrip™ mRNA-Anti-GPNMB, CDX-011 (DOX)(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))	mRNA	CDX-011 (DOX)
GTTS-WQ13189MR	IVTScrip™ mRNA-Anti-PCSK9, PF-04950615(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))	mRNA	PF-04950615
GTTS-WQ2609MR	IVTScrip™ mRNA-Anti-ICOSLG, AMG 557(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))	mRNA	AMG 557

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST